Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 01, 2015 6:58 AM ET

Healthcare Equipment and Supplies

Company Overview of CeloNova Biosciences, Inc.

Company Overview

CeloNova Biosciences, Inc. develops, manufactures, and markets products based upon the properties of Polyzene. It offers Embozene Microspheres, a spherical embolic device for the treatment of neurovascular arteriovenous malformations, hepatocellular carcinoma, hypervascularized tumors, and arteriovenous malformations. The company also provides CATANIA, a coronary stent system with nanothin Polyzene for the treatment of symptomatic ischemic heart disease due to de novo and obstructive lesions of native coronary arteries. It sells its products through distributors worldwide. CeloNova Biosciences, Inc. was formerly known as IMED Devices, Inc. and changed its name to CeloNova Biosciences, Inc. i...

18615 Tuscany Stone

Suite 100

San Antonio, TX 78258

United States

Founded in 2000





Key Executives for CeloNova Biosciences, Inc.

Chief Executive Officer
Age: 73
Chairman of the Board
Age: 67
Compensation as of Fiscal Year 2015.

CeloNova Biosciences, Inc. Key Developments

CeloNova's Super-Selective Embolic Microsphere with Drug Loading Capabilities Could Mean Improved Quality of Life and Overall Survival for Liver Cancer Patients

CeloNova BioSciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval to start an investigational device exemption (IDE) clinical trial for its novel ONCOZENE(TM) embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of Hepatocellular Carcinoma (HCC). HCC is the most common primary liver cancer and accounts for approximately 600,000 deaths annually on a worldwide basis. Untreated HCC patients have a median survival time of less than 12 months. CeloNova's ONCOZENE(TM) microspheres small sizes and precise calibration allow for super selective embolization combined with distal penetration which may greatly increase the chemotherapeutic impact at the tumor site, while lowering the toxicity in other parts of the body, thereby potentially improving the patient's tolerance of the treatment. CeloNova's TANDEM(TM) microspheres are available in Europe and bear the European Union's CE mark since it was granted in 2012 for embolization of HCC, with or without delivery of doxorubicin.

CeloNova BioSciences, Inc. Receives Expanded Indication in Liver Cancer

CeloNova BioSciences, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance expanding the indication for their innovative Oncozene(R) and Embozene(R) microsphere products to now include the embolization of Hepatoma. Hepatoma, also known as Hepatocellular Carcinoma (HCC). The FDA's clearance of Oncozene and Embozene for the embolization of Hepatoma provides support for another treatment option for physicians and patients in their battle against primary liver cancer.

CeloNova BioSciences, Inc. Receives FDA Approval to Start Investigative Device Exemption Trial for Cobra PzF(TM) Coronary Stent System

CeloNova BioSciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval to start an investigative device exemption (IDE) trial for its novel coronary stent system -- the Cobra PzF(TM) coronary stent system. Coronary stents are thin wire mesh devices used in minimally invasive heart surgery to prop open clogged blood vessels of the heart. The Cobra PzF coronary stent is made of Cobalt Chromium Super Alloy and is coated with an advanced nano-thin coating of Polyzene(R)-F polymer, which is approximately 100 times thinner than coating on currently available commercial coronary stents. Earlier generation Polyzene-F stents have been studied and results published in scientific journals. The company's Cobra PzF stent builds on this knowledge and improves on the earlier generation Polyzene-F stent technology. The IDE trial will study the Cobra PzF, Polyzene-F stent technology in patients with heart disease. It will enroll patients in multiple research centers across the United States and in Europe.

Similar Private Companies By Industry

Company Name Region
Whitmyer Biomechanix, Inc. United States
Adroit Medical Systems, Inc. United States
Human Touch, LLC United States
Sublase United States
CooperVision, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CeloNova Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at